From Itch to Innovation: The Emerging Role of Remibrutinib in Chronic Spontaneous Urticaria
Annals of Pharmacotherapy · 29.10.2026
DOI: 10.1177/10600280261495540 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Annals of Pharmacotherapy, online erschienen am 29.10.2026. Verfasst von Jessica Huston und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Education and Practice, College of Pharmacy, University of Florida, Jacksonville, USA. Die Arbeit nennt 36 Literaturangaben.
Abstract (Originalsprache)
Objective
This article reviews the published data encompassing the development, pharmacology, efficacy, and safety of remibrutinib, summarizing data from pivotal clinical studies and clinical relevance in the treatment of chronic spontaneous urticaria. Data Sources: A literature review was conducted in PubMed and ClinicalTrials.gov from inception through August 2026, using terms “RHAPSIDO,” “remibrutinib,” “LOU064,” and “chronic spontaneous urticaria.” Articles from reference lists were included to identify potentially relevant literature. Study Selection and Data Extraction: Clinical data and studies were limited to those published in the English language that discussed the safety and efficacy of remibrutinib. Data Synthesis: The pivotal phase III studies REMIX-1 (n = 470) and REMIX-2 (n = 455) met all primary endpoints at week 12, with Urticaria Activity Score over 7 days (UAS7) reductions of −20.02 and −19.41 versus −13.79 and −11.73 with placebo, parallel improvements in itch and hive severity, and complete absence of itch and hives in 31.1% and 27.9% versus 10.5% and 6.5%. Safety was comparable to placebo, with mild mucocutaneous bleeding (mainly petechiae) the only category significantly more frequent. Relevance to Patient Care and Clinical Practice in Comparison to Existing Drugs: As the first approved oral targeted Bruton’s tyrosine kinase (BTK) inhibitor, remibrutinib provides a new therapeutic option in chronic spontaneous urticaria treatment. Clinical practice is improved by the broadened evidence-based management option, which offers an oral pill alternative with no required routine lab monitoring in place of biologic injections.
Conclusion
Remibrutinib provides a new treatment option with the ability to control symptoms and improve quality of life for patients with difficult-to-treat chronic spontaneous urticaria.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy Education and Practice, College of Pharmacy, University of Florida, Jacksonville, USA.
- Sidney Kimmel Medical College, Philadelphia, PA, USA.
- PCOM South Georgia, Moultrie, USA.
- East Coast Institute for Research, Jacksonville, FL, USA.
- Florida State University, Tallahassee, USA.
- Jefferson Torresdale Hospital, Philadelphia, PA, USA.
ORCID-Profile: Jessica Huston, Lauren Carpenter, Kelli Corona, Rebecca Goldfaden
Zitieren
APA
Huston, J., Carpenter, L., Corona, K., Deeb, A., Deeb, E., Ashchi, A., Olabuntu, M., Asadi, A., Patton, I., Offiah, M., & Goldfaden, R. (2026). From Itch to Innovation: The Emerging Role of Remibrutinib in Chronic Spontaneous Urticaria. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280261495540
Vancouver
Huston J, Carpenter L, Corona K, Deeb A, Deeb E, Ashchi A, et al. From Itch to Innovation: The Emerging Role of Remibrutinib in Chronic Spontaneous Urticaria. Annals of Pharmacotherapy. 2026. doi:10.1177/10600280261495540
BibTeX
@article{Huston2026,
author = {Huston, Jessica and Carpenter, Lauren and Corona, Kelli and Deeb, Alexander and Deeb, Elias and Ashchi, Andrew and Olabuntu, Mariam and Asadi, Adam and Patton, Inara and Offiah, Maureen and Goldfaden, Rebecca},
title = {From Itch to Innovation: The Emerging Role of Remibrutinib in Chronic Spontaneous Urticaria},
journal = {Annals of Pharmacotherapy},
year = {2026},
doi = {10.1177/10600280261495540}
}
EUVIMED